Tirzepatide as Compared with Semaglutide for the Treatment of Obesity

Тирзепатид по сравнению с семаглутидом для лечения ожирения
Clare J. Lee, Louis J. Aronne, Carel Wynand le Roux, Leonard C. Glass, Deborah Bade Horn, Julia P. Dunn, Elisa Gomez Valderas, Wayne Ho, Beverly L. Falcón, Sagar Das, Çağrı Şenyücel
2025-05-11

Obesity managementSemaglutideTirzepatideWaist circumferenceWeight reduction
BACKGROUND: Tirzepatide and semaglutide are highly effective medications for obesity management. The efficacy and safety of tirzepatide as compared with semaglutide in adults with obesity but without type 2 diabetes is unknown. METHODS: In this phase 3b, open-label, controlled trial, adult participants with obesity but without type 2 diabetes were randomly assigned in a 1:1 ratio to receive the maximum tolerated dose of tirzepatide (10 mg or 15 mg) or the maximum tolerated dose of semaglutide (1.7 mg or 2.4 mg) subcutaneously once weekly for 72 weeks. The primary end point was the percent change in weight from baseline to week 72. Key secondary end points included weight reductions of at least 10%, 15%, 20%, and 25% and a change in waist circumference from baseline to week 72. RESULTS: A total of 751 participants underwent randomization. The least-squares mean percent change in weight at week 72 was -20.2% (95% confidence interval [CI], -21.4 to -19.1) with tirzepatide and -13.7% (95% CI, -14.9 to -12.6) with semaglutide (P<0.001). The least-squares mean change in waist circumference was -18.4 cm (95% CI, -19.6 to -17.2) with tirzepatide and -13.0 cm (95% CI, -14.3 to -11.7) with semaglutide (P<0.001). Participants in the tirzepatide group were more likely than those in the semaglutide group to have weight reductions of at least 10%, 15%, 20%, and 25%. The most common adverse events in both treatment groups were gastrointestinal, and most were mild to moderate in severity and occurred primarily during dose escalation. CONCLUSIONS: Among participants with obesity but without diabetes, treatment with tirzepatide was superior to treatment with semaglutide with respect to reduction in body weight and waist circumference at week 72. (Funded by Eli Lilly; SURMOUNT-5 ClinicalTrials.gov number, NCT05822830.).
1
Gastrointestinal adverse events were most common with both treatments, generally mild to moderate, and occurred mainly during dose escalation.
2
In a 72-week phase 3b trial of 751 adults with obesity without type 2 diabetes, tirzepatide produced greater weight loss than semaglutide.
3
Mean waist circumference reduction was -18.4 cm with tirzepatide versus -13.0 cm with semaglutide (P<0.001).
4
Mean weight change at week 72 was -20.2% with tirzepatide versus -13.7% with semaglutide (P<0.001).
5
Participants receiving tirzepatide were more likely to achieve at least 10%, 15%, 20%, and 25% weight loss.

Adults with obesity without type 2 diabetes treated with tirzepatide or semaglutide

Comparative efficacy and safety, including reductions in body weight and waist circumference over 72 weeks

Publication Details
Publication Date
2025-05-11
Journal
Publisher
ISSN
Cited by
756
Access Type
Author Information
Authors
Clare J. Lee
Louis J. Aronne
Carel Wynand le Roux
Leonard C. Glass
Deborah Bade Horn
Julia P. Dunn
Elisa Gomez Valderas
Wayne Ho
Beverly L. Falcón
Sagar Das
Çağrı Şenyücel
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%